27692696|t|De Ritis Ratio (AST/ALT) as a Significant Prognostic Factor in Patients With Upper Tract Urothelial Cancer Treated With Surgery
27692696|a|We investigated the clinical prognostic value of preoperative De Ritis ratio (aspartate aminotransferase [AST]/alanine aminotransferase [ALT]) on postsurgical survival outcomes in patients with upper tract urothelial cancer (UTUC). We retrospectively analyzed the data of 623 patients who underwent radical nephrouretectomy for UTUC. Multivariate regression tests were performed to identify possible associations between adverse pathologic events and AST/ALT. The risk of postoperative progression and survival were tested using Kaplan-Meier analyses and Cox proportional hazards models. According to the receiver operator characteristic curve of AST/ALT for cancer-specific mortality, patients with AST/ALT value â‰¥1.5 were regarded as the high AST/ALT group, and the remaining patients formed the low AST/ALT group. In Kaplan-Meier analyses, the high AST/ALT group showed worse progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (all P < .001). Elevated AST/ALT was associated with higher T stage (hazard ratio [HR], 1.577; 95% confidence interval [CI], 1.077-2.311; P = .033) and higher cellular grade (HR, 1.538; 95% CI, 1.034-2.287; P = .041) in multivariate regression tests. In multivariate Cox analyses, high AST/ALT was revealed as an independent predictor of PFS (HR, 2.335; 95% CI, 1.633-3.340; P < .001), CSS (HR, 2.550; 1.689-3.851; P < .001), and overall survival (HR, 2.069; 95% CI, 1.409-3.038; P < .001). Elevated preoperative AST/ALT was a significant predictor of worse postoperative survival in patients surgically treated for UTUC. Further large prospective studies are needed for better understanding of the prognostic value of preoperative AST/ALT.
27692696	0	24	De Ritis Ratio (AST/ALT)	T201	C0364051
27692696	30	59	Significant Prognostic Factor	T201	C1514474
27692696	63	71	Patients	T101	C0030705
27692696	77	106	Upper Tract Urothelial Cancer	T191	C0751571
27692696	107	114	Treated	T169	C1522326
27692696	120	127	Surgery	T169	C0038895
27692696	131	143	investigated	T169	C1292732
27692696	148	173	clinical prognostic value	T170	C0220901
27692696	177	189	preoperative	T079	C0445204
27692696	190	270	De Ritis ratio (aspartate aminotransferase [AST]/alanine aminotransferase [ALT])	T201	C0364051
27692696	274	286	postsurgical	T033	C0231287
27692696	287	295	survival	T052	C0038952
27692696	296	304	outcomes	T169	C1274040
27692696	308	316	patients	T101	C0030705
27692696	322	351	upper tract urothelial cancer	T191	C0751571
27692696	353	357	UTUC	T191	C0751571
27692696	363	387	retrospectively analyzed	T062	C0035363
27692696	392	396	data	T078	C1511726
27692696	404	412	patients	T101	C0030705
27692696	427	451	radical nephrouretectomy	T061	C0027732
27692696	456	460	UTUC	T191	C0751571
27692696	462	485	Multivariate regression	T080	C0681923
27692696	486	491	tests	T170	C0392366
27692696	519	540	possible associations	T080	C0439849
27692696	549	574	adverse pathologic events	T046	C0030660
27692696	579	586	AST/ALT	T201	C0364051
27692696	600	613	postoperative	T079	C0032790
27692696	614	625	progression	T169	C0449258
27692696	630	638	survival	T052	C0038952
27692696	644	650	tested	T169	C0039593
27692696	657	678	Kaplan-Meier analyses	T081	C1720943
27692696	683	714	Cox proportional hazards models	T081,T170	C0010235
27692696	733	771	receiver operator characteristic curve	T081	C0034772
27692696	775	782	AST/ALT	T201	C0364051
27692696	787	812	cancer-specific mortality	T081	C1516192
27692696	814	822	patients	T101	C0030705
27692696	828	835	AST/ALT	T201	C0364051
27692696	873	880	AST/ALT	T201	C0364051
27692696	906	914	patients	T101	C0030705
27692696	930	937	AST/ALT	T201	C0364051
27692696	948	969	Kaplan-Meier analyses	T081	C1720943
27692696	980	987	AST/ALT	T201	C0364051
27692696	1007	1032	progression-free survival	T081	C0242792
27692696	1034	1037	PFS	T081	C0242792
27692696	1040	1064	cancer-specific survival	T081	C0038954
27692696	1066	1069	CSS	T081	C0038954
27692696	1076	1092	overall survival	T081	C4086681
27692696	1118	1125	AST/ALT	T201	C0364051
27692696	1130	1145	associated with	T080	C0332281
27692696	1153	1160	T stage	T185	C0475455
27692696	1162	1174	hazard ratio	T081	C2985465
27692696	1176	1178	HR	T081	C2985465
27692696	1192	1211	confidence interval	T081	C0009667
27692696	1213	1215	CI	T081	C0009667
27692696	1245	1266	higher cellular grade	T185	C0441800
27692696	1268	1270	HR	T081	C2985465
27692696	1283	1285	CI	T081	C0009667
27692696	1313	1336	multivariate regression	T080	C0681923
27692696	1337	1342	tests	T170	C0392366
27692696	1347	1372	multivariate Cox analyses	T081	C0026777
27692696	1379	1386	AST/ALT	T201	C0364051
27692696	1406	1427	independent predictor	T078	C2698872
27692696	1431	1434	PFS	T081	C0242792
27692696	1436	1438	HR	T081	C2985465
27692696	1451	1453	CI	T081	C0009667
27692696	1479	1482	CSS	T081	C0038954
27692696	1484	1486	HR	T081	C2985465
27692696	1523	1539	overall survival	T081	C4086681
27692696	1541	1543	HR	T081	C2985465
27692696	1556	1558	CI	T081	C0009667
27692696	1593	1605	preoperative	T079	C0445204
27692696	1606	1613	AST/ALT	T201	C0364051
27692696	1620	1641	significant predictor	T078	C2698872
27692696	1645	1650	worse	T033	C1457868
27692696	1651	1664	postoperative	T079	C0032790
27692696	1665	1673	survival	T052	C0038952
27692696	1677	1685	patients	T101	C0030705
27692696	1686	1704	surgically treated	T061	C0543467
27692696	1709	1713	UTUC	T191	C0751571
27692696	1729	1748	prospective studies	T062	C0033522
27692696	1792	1808	prognostic value	T170	C0220901
27692696	1812	1824	preoperative	T079	C0445204
27692696	1825	1832	AST/ALT	T201	C0364051